| Relay Therapeutics to Participate in Two Upcoming Investor Conferences |
CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in two upcoming fireside chats: |
globenewswire.com |
2025-05-08 20:05:00 |
Czytaj oryginał (ang.) |
| Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates |
Cash runway extended into 2029 Initiation of Phase 3 ReDiscover-2 trial on track for mid-2025 Initiated Phase 1 RLY-2608 vascular malformations clinical trial in Q1 Extended cash runway expected to fully fund the Company meaningfully past topline data for ReDiscover-2 trial and through clinical proof-of-concept data in Vascular Malformations Approximately $710 million in cash, cash equivalents and investments at end of Q1 2025 CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported first quarter 2025 financial results and corporate updates. |
globenewswire.com |
2025-05-05 20:05:00 |
Czytaj oryginał (ang.) |
| Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025 |
CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report first quarter 2025 financial results and corporate highlights after the U.S. financial markets close on Monday, May 5, 2025. |
globenewswire.com |
2025-04-28 20:05:00 |
Czytaj oryginał (ang.) |
| Top Cancer Stocks to Buy to Boost Your Portfolio's Health |
If the cancer space appeals to you, it's time to consider stocks like Pyxis Oncology, Verastem Oncology and Relay Therapeutics. |
zacks.com |
2025-04-16 14:46:10 |
Czytaj oryginał (ang.) |
| Relay Therapeutics: Trying To Find That Right Price |
Relay Therapeutics' pipeline has shifted, with the FGFR2 inhibitor lirafugratinib outlicensed to Elevar, bringing in cash and royalties, but losing global rights. RLY-2608, a PI3K-alpha inhibitor, shows promise in breast cancer trials, with plans for a phase 3 trial and potential in other cancers. Financially, RLAY holds $124.3M in cash and $657M in investments, with a cash runway into mid-2026, bolstered by recent cost-saving measures. |
seekingalpha.com |
2025-04-12 13:28:20 |
Czytaj oryginał (ang.) |
| Down -31.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Relay Therapeutics (RLAY) |
The heavy selling pressure might have exhausted for Relay Therapeutics (RLAY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
zacks.com |
2025-03-05 12:36:12 |
Czytaj oryginał (ang.) |
| Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates |
Initiation of Phase 3 ReDiscover-2 trial of RLY-2608 + fulvestrant anticipated in the middle of 2025 in PI3Kα-mutated, CDK4/6 pre-treated, HR+/HER2- metastatic breast cancer |
globenewswire.com |
2025-02-26 18:05:00 |
Czytaj oryginał (ang.) |
| Relay Therapeutics to Participate in Two Upcoming Investor Conferences |
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in two upcoming fireside chats: TD Cowen's 45th Annual Health Care Conference on Wednesday, March 5, 2025 at 1:50 p.m. |
globenewswire.com |
2025-02-24 18:05:00 |
Czytaj oryginał (ang.) |
| Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025 |
CAMBRIDGE, Mass., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report fourth quarter and full year 2024 financial results and corporate highlights after the U.S. financial markets close on Wednesday, February 26, 2025. |
globenewswire.com |
2025-02-19 18:05:00 |
Czytaj oryginał (ang.) |
| Relay Therapeutics: A Precision Oncology Play Worth The Risk |
Relay Therapeutics focuses on selective small-molecule inhibitors, with RLY-2608 showing promise in breast cancer and a solid cash position lasting into 2027. Financial stability is strong, but zero Q3 2024 revenue and rising net losses raise concerns about expense control and sustainable cash flow. Out-licensing RLY-4008 to Elevar Therapeutics secures up to $500 million in milestones, allowing RLAY to concentrate on RLY-2608's clinical trials. |
seekingalpha.com |
2025-02-14 04:17:32 |
Czytaj oryginał (ang.) |
| Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference |
CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that Sanjiv Patel, M.D., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 7:30 a.m. PT. |
globenewswire.com |
2025-01-07 18:05:00 |
Czytaj oryginał (ang.) |
| Relay Therapeutics (RLAY) Moves to Buy: Rationale Behind the Upgrade |
Relay Therapeutics (RLAY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-12-20 15:01:20 |
Czytaj oryginał (ang.) |
| Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival |
New interim data show 11.4-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D |
globenewswire.com |
2024-12-11 08:00:00 |
Czytaj oryginał (ang.) |
| Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium |
Company to host conference call on Wednesday, December 11, 2024 at 7am ET Company to host conference call on Wednesday, December 11, 2024 at 7am ET |
globenewswire.com |
2024-12-09 18:05:00 |
Czytaj oryginał (ang.) |
| After Plunging -30.29% in 4 Weeks, Here's Why the Trend Might Reverse for Relay Therapeutics (RLAY) |
Relay Therapeutics (RLAY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
zacks.com |
2024-12-06 12:35:17 |
Czytaj oryginał (ang.) |
| Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors |
Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008) |
globenewswire.com |
2024-12-03 10:01:00 |
Czytaj oryginał (ang.) |
| Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors |
Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008) |
globenewswire.com |
2024-12-03 10:00:00 |
Czytaj oryginał (ang.) |
| Down -27.93% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround |
The heavy selling pressure might have exhausted for Relay Therapeutics (RLAY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
zacks.com |
2024-11-20 12:35:26 |
Czytaj oryginał (ang.) |
| Down -23.95% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround |
The heavy selling pressure might have exhausted for Relay Therapeutics (RLAY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
zacks.com |
2024-11-19 12:35:40 |
Czytaj oryginał (ang.) |
| Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights |
Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D |
globenewswire.com |
2024-11-06 18:05:00 |
Czytaj oryginał (ang.) |
| Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024 |
CAMBRIDGE, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report third quarter 2024 financial results and corporate highlights after the U.S. financial markets close on Wednesday, November 6, 2024. |
globenewswire.com |
2024-10-30 18:05:00 |
Czytaj oryginał (ang.) |
| Strength Seen in Relay Therapeutics (RLAY): Can Its 6.7% Jump Turn into More Strength? |
Relay Therapeutics (RLAY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term. |
zacks.com |
2024-09-17 13:26:30 |
Czytaj oryginał (ang.) |
| Relay Therapeutics: 2nd-Line RLY-2608 Data Moves Program Towards Expansion |
Relay Therapeutics, Inc. reported positive interim data from its phase 1 ReDiscover study, using RLY-2608 + fulvestrant for treatment of PI3Ka-mutated HR+/HER2- locally advanced or metastatic breast cancer patients. Key upcoming milestones for RLY-2608 program includes presenting data at the San Antonio Breast Cancer Symposium in December 2024 and initiating a phase 3 study in 2025. Expansion opportunities of the RLY-2608 program includes two triplet regimens targeting 1st-line PI3Ka-mutant HR+/HER2- breast cancer patients and phase 1 study for tumors with vascular formations starting in Q1 2025. |
seekingalpha.com |
2024-09-16 20:57:53 |
Czytaj oryginał (ang.) |
| Why Relay Therapeutics Plummeted by Nearly 14% Today |
The biotech firmed up the details of its upcoming secondary share issue. However, the flotation will be dilutive to existing shareholders. |
fool.com |
2024-09-11 22:46:10 |
Czytaj oryginał (ang.) |
| Relay Therapeutics' RLY-2608 Shows Promise For Breast Cancer With PI3Kα Mutations |
Relay Therapeutics' Dynamo platform combines machine learning and physics-based simulation to target dynamic protein conformations for oncology and genetic disease therapies. RLY-2608 targets PI3Kα-mutated HR+/HER2- breast cancer, with promising Phase 2 results and potential approval by 2026-2027. The company's RLY-4008 targets FGFR2-altered cholangiocarcinoma, and it is seeking pivotal trials and a commercialization partner to unlock broader market potential. |
seekingalpha.com |
2024-09-11 12:15:57 |
Czytaj oryginał (ang.) |
| GameStop Reports Weak Sales, Joins Petco, Relay Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session |
U.S. stock futures were lower this morning, with the Dow futures falling around 150 points on Wednesday. |
benzinga.com |
2024-09-11 12:06:25 |
Czytaj oryginał (ang.) |
| Relay Therapeutics Announces Pricing of Public Offering of Common Stock |
CAMBRIDGE, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today the pricing of an underwritten public offering of 28,571,429 shares of its common stock at a public offering price of $7.00 per share. |
globenewswire.com |
2024-09-11 00:21:00 |
Czytaj oryginał (ang.) |
| Relay Therapeutics Faces Downgrade Over Efficacy Concerns in Competitive PI3K Inhibitor Market |
Monday, Relay Therapeutics Inc. RLAY shared interim data for RLY-2608 from the ReDiscover study of RLY-2608 alone, in combination with fulvestrant, and in combination with fulvestrant and ribociclib or atirmociclib (Pfizer Inc's PFE selective CDK4 inhibitor). |
benzinga.com |
2024-09-10 18:50:27 |
Czytaj oryginał (ang.) |
| Relay Stock Soars on Upbeat Data From Breast Cancer Study |
RLAY stock soars on positive interim efficacy data from the early-stage study of its doublet therapy, RLY-2608 in combination with Faslodex, for treating MBC. |
zacks.com |
2024-09-10 15:55:33 |
Czytaj oryginał (ang.) |
| Relay Therapeutics Announces Proposed Public Offering of Common Stock |
CAMBRIDGE, Mass., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today that it has commenced an underwritten public offering of $200 million of shares of its common stock. |
globenewswire.com |
2024-09-09 20:34:00 |
Czytaj oryginał (ang.) |
| Crude Oil Gains Over 1%; Relay Therapeutics Shares Spike Higher |
U.S. stocks traded higher toward the end of trading, with the S&P 500 gaining around 1% on Monday. |
benzinga.com |
2024-09-09 18:16:34 |
Czytaj oryginał (ang.) |